Oxford Biomedica Takeover Rumours (OXB)

If the FTC block Novo takeover of Catalent,where else could they go for capacity?NEW YORK, Oct 17 (Reuters) - U.S. consumer groups and two large labour unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, from acquiring contract drug manufacturer Catalent (CTLT.N), opens new tab, saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.

Having just received the takeover proceeds from another (sad) US takeover of a UK company, why should I complain if market manipulation means I can now add some more OXB 5 or 10% cheaper than I was expecting?

I would say it's either a coincidence or that they are up to something which some people have twigged. They don't need money and if it was a fundraising the price would be going the other way. Takeover brewing is really unlikely as we have some big holders who collectively own more than half. Malaria is the obvious guess, but that has been hovering for so long now. The CAR-T news they have already basically told us all but the names and the size. Something else?

Interesting. Must have been intimately involved in the NVS takeover if the CFO "Lucinda Crabtree was previously CFO at MorphoSys AG. As CFO of MorphoSys, Lucy led a finance team across the US and Germany until the closing of the acquisition of the company by Novartis. "

Sentiment in all equity markets oscillates between the morose to the ebullient dictating the valuation that is applied to any stock at any given time regardless of the fundamentals.Currently,the UK equity market is morose and i don’t trust the market to apply an accurate rating to a whole multitude of stocks,illiquid,smaller stocks in particular.The markets perception of OXB has gone from the short-lived ‘ebullience’ attached to being a high profile beneficiary of covid to the ‘morose’ perception of an unloved orphan in the post covid era.I don’t think the market has remotely addressed itself to the metamorphosis that OXB is undertaking to becoming a highly profitable,cash flow generative,pure CDMO.The real question is whether the market will wake its ideas up before OXB receives a takeover approach.

Harry….your comments on possible news flow are interesting. In a nutshell it seems to me we are being buoyed up on three fronts:-1. An improving profile as regards trading/turnaround prospects;2. Genuine takeover possibilities from pharmaceutical companies with very deep pockets;3. An sp that has dived by c.90% from its peak.As I have said before, OXB clearly has some very rich friends. Certainly enough to maintain my interest.